Literature DB >> 33741223

Radiotherapy: An immune response modifier for immuno-oncology.

Mara De Martino1, Camille Daviaud1, Claire Vanpouille-Box2.   

Abstract

The ability of radiotherapy to enhance antigenicity and adjuvanticity of an irradiated tumor has stimulated the interest for its combination with immuno-oncology agents. However, radiotherapy often generates multiple layers of host responses which likely depends on the tumor biology, the immune cell infiltration and the induction of immunosuppressive signals post radiotherapy. Consequently, translation of preclinical findings to the clinic is more convoluted than anticipated which underscore the need to decipher molecular and cellular mechanisms elicited by radiotherapy. Here we review pro-inflammatory and immunosuppressive mechanisms triggered by radiotherapy that impact the outcome of antigen specific T cell killing and discuss how radiation-induced immunostimulatory mechanisms can be exploited to reactivate the host's immune system, especially in the context of immunotherapy.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Adjuvanticity; Immunosuppression; Nucleic acid sensing; Radiotherapy; Tumor microenvironment; Type I interferon

Mesh:

Year:  2021        PMID: 33741223     DOI: 10.1016/j.smim.2021.101474

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  7 in total

1.  Radiomitigation by Melatonin in C57BL/6 Mice: Possible Implications as Adjuvant in Radiotherapy and Chemotherapy.

Authors:  Akanchha Mani Tripathi; Shahanshah Khan; Nabo Kumar Chaudhury
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

2.  Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp.

Authors:  Davide Quaresmini; Alessandra Di Lauro; Livia Fucci; Sabino Strippoli; Ivana De Risi; Angela Monica Sciacovelli; Anna Albano; Gaetano Achille; Massimo Montepara; Sabino Russo; Gabriella Tassone; Michele Guida
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

Review 3.  Emerging Bismuth Chalcogenides Based Nanodrugs for Cancer Radiotherapy.

Authors:  Jia Huang; Qiong Huang; Min Liu; Qiaohui Chen; Kelong Ai
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

4.  Immunomodulatory effect of splenectomy in lung cancer mouse xenograft models receiving radiation therapy.

Authors:  Yeeun Kim; Changhoon Choi; Jee Hyun Park; Won-Gyun Ahn; Sung-Won Shin; Shin-Yeong Kim; Jae Myoung Noh
Journal:  Radiat Oncol J       Date:  2022-02-23

5.  Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy.

Authors:  Shijin Liu; Yiran Zhang; Yujian Lin; Peize Wang; Yunlong Pan
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

6.  Immune radiobiology.

Authors:  Claire Vanpouille-Box
Journal:  J Transl Med       Date:  2021-06-10       Impact factor: 5.531

Review 7.  Exploiting Radiation Therapy to Restore Immune Reactivity of Glioblastoma.

Authors:  Mara De Martino; Oscar Padilla; Camille Daviaud; Cheng-Chia Wu; Robyn D Gartrell; Claire Vanpouille-Box
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.